echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roche's atezolizumab approved for perioperative adjuvant therapy in early stage lung cancer

    Roche's atezolizumab approved for perioperative adjuvant therapy in early stage lung cancer

    • Last Update: 2022-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 18, Roche announced that the NMPA officially approved the company's innovative tumor immune drug atezolizumab as a single drug for detection and evaluation of ≥1% tumor cells (TC) with positive PD-L1 staining, surgical resection, and tumor cells.


    Lung cancer is one of the most common malignancies in the world, and NSCLC is the most common type, accounting for approximately 85% of all cases


    Adjuvant chemotherapy is currently the most widely used adjuvant therapy, but chemotherapy drugs have relatively large side effects and bring relatively limited survival benefits to patients, which can only improve the 5-year survival rate of patients by an average of 4-5%


    NMPA approved this indication this time, mainly based on the research results of IMpower010


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.